Abstract
Viral vector systems are widely being used in the development of new genetic approaches for a variety of human diseases. Oncolytic viruses have shown great potential as cancer therapeutics. The ideal viral vector for cancer gene therapy eradicates a clinically significant fraction of malignant cells and leaves normal tissues unharmed. The Edmonston vaccine strain of measles virus is a replicating RNA virus which is characterized by its tumor selectivity and oncolysis. Its strong tumor suppressive potential combined with its excellent safety record as a viral vaccine makes it an optimal platform for oncolytic virotherapy of cancer. Recent advances in genetic engineering of measles virus allow insertion of therapeutic and diagnostic transgenes as well as complete retargeting of measles virus. These strategies resulted in the generation of recombinant measles viruses allowing non-invasive monitoring of viral replication and viral spread. The immune defense is a significant barrier for efficient viral gene therapy. Immune-evasive strategies have successfully been developed for measles virus enhancing its efficacy. This review gives an overview of measles virus as an anticancer agent; in particular, its use in oncologic virotherapy as well as new developments in targeting and immune evasive strategies.
Keywords: Ovarian Cancer, immune system, Signaling lymphocyte activation molecule, Antiviral Antibodies, B-Cell Non-Hodkin Lymphoma, Glioblastoma multiforme
Current Gene Therapy
Title: Measles Virus as An Oncolytic Vector Platform
Volume: 8 Issue: 3
Author(s): Boris Blechacz and Stephen J. Russell
Affiliation:
Keywords: Ovarian Cancer, immune system, Signaling lymphocyte activation molecule, Antiviral Antibodies, B-Cell Non-Hodkin Lymphoma, Glioblastoma multiforme
Abstract: Viral vector systems are widely being used in the development of new genetic approaches for a variety of human diseases. Oncolytic viruses have shown great potential as cancer therapeutics. The ideal viral vector for cancer gene therapy eradicates a clinically significant fraction of malignant cells and leaves normal tissues unharmed. The Edmonston vaccine strain of measles virus is a replicating RNA virus which is characterized by its tumor selectivity and oncolysis. Its strong tumor suppressive potential combined with its excellent safety record as a viral vaccine makes it an optimal platform for oncolytic virotherapy of cancer. Recent advances in genetic engineering of measles virus allow insertion of therapeutic and diagnostic transgenes as well as complete retargeting of measles virus. These strategies resulted in the generation of recombinant measles viruses allowing non-invasive monitoring of viral replication and viral spread. The immune defense is a significant barrier for efficient viral gene therapy. Immune-evasive strategies have successfully been developed for measles virus enhancing its efficacy. This review gives an overview of measles virus as an anticancer agent; in particular, its use in oncologic virotherapy as well as new developments in targeting and immune evasive strategies.
Export Options
About this article
Cite this article as:
Blechacz Boris and Russell J. Stephen, Measles Virus as An Oncolytic Vector Platform, Current Gene Therapy 2008; 8 (3) . https://dx.doi.org/10.2174/156652308784746459
DOI https://dx.doi.org/10.2174/156652308784746459 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Hedgehog Signaling and Urological Cancers
Current Drug Targets MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Editorial [Hot Topic: Development of Drugs Interfering with Apoptosis (Executive Guest Editor: Sebastiano Cavallaro)]
Current Pharmaceutical Design Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography
Medicinal Chemistry Chromosome 17 in Fronto Temporal Lobak Degeneration (FTLD): From MAPT to Progranulin and Back
Current Alzheimer Research Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Current Gene Therapy Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides
Current Medicinal Chemistry An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Editorial [Hot Topic: Target Therapy in Brain Tumours and Metastases (Guest Editors: M. Caraglia and R. Addeo)]
Current Cancer Drug Targets Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology